JP5537933B2 - 変形性骨関節炎を治療するための硫酸化ヒアルロン酸 - Google Patents
変形性骨関節炎を治療するための硫酸化ヒアルロン酸 Download PDFInfo
- Publication number
- JP5537933B2 JP5537933B2 JP2009512441A JP2009512441A JP5537933B2 JP 5537933 B2 JP5537933 B2 JP 5537933B2 JP 2009512441 A JP2009512441 A JP 2009512441A JP 2009512441 A JP2009512441 A JP 2009512441A JP 5537933 B2 JP5537933 B2 JP 5537933B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hyaluronic acid
- treatment
- osteoarthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、変形性骨関節炎の治療において有効である硫酸化ヒアルロン酸に基づく、経口製剤および関節内製剤に関する。
骨関節炎(OA)は、細胞成分および細胞外成分の喪失の後に薄化し、劣化し、完全に消失することさえあり得る、関節軟骨の進行性変性を特徴とする、非常に一般的な障害である。この疾患の原因は、部分的にしか明らかでない。原因には、基本的に、例えば、外傷または機械的ストレス後の、関節全体に影響する力学的不均衡によって誘発される、一連のプロセスが関与していると思われる。軟骨の内部では、消耗した細胞外基質の破壊とインタクトな基質の形成との間で、繊細な均衡が存在する。すべてこれは、関節基質の細胞成分である、軟骨細胞によって産生される酵素に大きく依存する。関節上に過剰または不均衡な負荷がかかる事象では、炎症性状況が生じる。これは、炎症性サイトカインの放出を誘発し、これは次に、軟骨細胞を刺激して軟骨の破壊に関与する酵素である、メタロプロテアーゼ(MMP)を産生させ、こうして細胞外基質の合成と分解との間の均衡を変化させる。科学文献にも、軟骨細胞が、基質の崩壊によって産生される物質に接触するとき、軟骨細胞に影響する細胞死プロセスが詳細に記載されている(Caoら、Exp Cell Res、1999、246:527−37)。
− ヒアルロン酸(HA)の骨格、
− グルコサミンまたはガラクトサミンの繰り返し二糖単位を含有し、さらには、負に帯電したカルボキシル基またはサルフェート基を保有し、その結果、長い負に帯電した鎖を形成する、グリコサミノグリカン(GAG)、
− ポリペプチド
によって形成される。
本発明は、炎症後遺症を伴わない、慢性形態の変形性骨関節炎の(好ましくは経口)治療において有効である、硫酸化によって化学的に修飾されたHAに基づく製剤に関する。
− ゾーンI:部分的にしか細胞化(cellularised)していない、最も薄い、最も外側の部分、
− ゾーンII:最も高い割合の細胞を含有し、基質生成に基本的に関与する、移行ゾーン、
− ゾーンIII:最も大きく、軟骨の全体の厚さがその構造に依存する、放射状ゾーン、
− ゾーンIV:放射状ゾーンを軟骨下骨から分離する薄層である、石灰化ゾーン
に分割することができる。
実験は、現在の法律を厳密に遵守して、成体ウサギで行った。十分に確立した実験モデル(Yoshimiら、Clin Orthop Relat Res、1994、298:296−304)による、前十字靭帯の外科的切除によって、右膝の変形性骨関節炎を一側性に誘導した。使用した実験モデルでは、対照を含めたすべての処置動物の関節腔において血漿浸潤物がまったくないことにより実証されるように、炎症プロセスが誘発されない(表)。靭帯の外科的アブレーションは、実験的変形性骨関節炎の良好な例を表し、これにより、試験した製剤の正確な薬理学的評価が可能になる。
− 0.9%のNaClの食塩液(対照)、
− 5.5mg/kgの用量でのHA−S、
− 20mg/kgの用量でのHA、
− 20mg/kgの用量でのCondral(登録商標)
を用いて経口的に処置した。
これらの製剤に使用されるHAは、1の平均硫酸化度および180/200KDの平均分子量を有する。活性成分の濃度は、1用量単位当たり50と400mgの間の範囲である。
180/200KDまたは500/750KDの平均分子量を有し、1〜100mg/ml、好ましくは5〜50mg/ml、およびさらにより好ましくは10〜20mg/mlの濃度で、滅菌無発熱物質食塩液中に調製された、HA−Sグレード1または2が、注射用関節内調製物用に使用されることが好ましい。最終溶液は、滅菌で無発熱物質でなければならない。これは、凍結乾燥し、使用時に再構成することもできる。
Claims (17)
- 炎症症状を有しない慢性変形性骨関節炎および/または関節構造の老化による磨耗によって生じる軟骨損傷の予防および/または治療用の、硫酸化ヒアルロン酸を含有する医薬組成物。
- 前記ヒアルロン酸の分子量が50000と800000Dの間である、請求項1に記載の医薬組成物。
- 前記ヒアルロン酸の分子量が100000と230000Dの間である、請求項2に記載の医薬組成物。
- 前記ヒアルロン酸の分子量が500000と750000Dの間である、請求項2に記載の医薬組成物。
- 前記硫酸化ヒアルロン酸の硫酸化度が0.5と3.5の間である、請求項1から4のいずれか1項に記載の医薬組成物。
- 前記硫酸化ヒアルロン酸の硫酸化度が0.5と1.5の間である、請求項5に記載の医薬組成物。
- 前記ヒアルロン酸が、抽出、発酵、または技術的手段によって生成される、請求項1に記載の医薬組成物。
- コラーゲンおよび/または加水分解コラーゲンおよび/またはグリコサミノグリカンを含有する、請求項1から7のいずれか1項に記載の医薬組成物。
- 薬理学的および/または生物学的活性物質を含有する、請求項1から7、および8のいずれか1項に記載の医薬組成物。
- 前記薬理学的および/または生物学的活性物質が、ビタミンおよび/または無機塩類および/またはホルモンおよび/または抗生物質および/または成長因子の群から選択される、請求項9に記載の医薬組成物。
- 炎症症状を有しない慢性変形性骨関節炎および/または関節構造の老化による磨耗によって生じる軟骨損傷の経口投与による予防および/または経口治療用の、請求項1から10のいずれか1項に記載の医薬組成物。
- 硫酸化ヒアルロン酸の濃度が、1用量単位当たり75と400mgの間である、請求項11に記載の医薬組成物。
- 炎症症状を有しない慢性変形性骨関節炎および/または関節構造の老化による磨耗によって生じる軟骨損傷の関節内治療用の、請求項1から10のいずれか1項に記載の医薬組成物。
- 硫酸化ヒアルロン酸の濃度が1と100mg/mlの間である、請求項13に記載の医薬組成物。
- 硫酸化ヒアルロン酸の前記濃度が10と20mg/mlの間である、請求項14に記載の医薬組成物。
- 炎症症状を有しない慢性変形性骨関節炎および/または関節構造の老化による磨耗によって生じる軟骨損傷の経口投与による予防および/または経口治療用の請求項11または12に記載の医薬組成物を含む製剤の調製のための、硫酸化ヒアルロン酸の使用。
- 炎症症状を有しない慢性変形性骨関節炎および/または関節構造の老化による磨耗によって生じる軟骨損傷の関節内治療用の請求項13から15のいずれか1項に記載の医薬組成物を含む注射製剤を調製するための、硫酸化ヒアルロン酸の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000219A ITPD20060219A1 (it) | 2006-05-31 | 2006-05-31 | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
ITPD2006A000219 | 2006-05-31 | ||
PCT/EP2007/003920 WO2007137674A1 (en) | 2006-05-31 | 2007-05-03 | Sulphated hyaluronic acid for treating degenerative osteoarthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009538840A JP2009538840A (ja) | 2009-11-12 |
JP5537933B2 true JP5537933B2 (ja) | 2014-07-02 |
Family
ID=38353080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512441A Expired - Fee Related JP5537933B2 (ja) | 2006-05-31 | 2007-05-03 | 変形性骨関節炎を治療するための硫酸化ヒアルロン酸 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20090197807A1 (ja) |
EP (2) | EP2021078B1 (ja) |
JP (1) | JP5537933B2 (ja) |
KR (1) | KR20090014359A (ja) |
CN (1) | CN101454048B (ja) |
AU (1) | AU2007268195A1 (ja) |
CA (1) | CA2653660C (ja) |
DK (1) | DK2021078T3 (ja) |
ES (2) | ES2619309T3 (ja) |
HK (2) | HK1123235A1 (ja) |
IT (1) | ITPD20060219A1 (ja) |
MX (1) | MX2008015212A (ja) |
PL (2) | PL2786782T3 (ja) |
SI (2) | SI2021078T1 (ja) |
WO (1) | WO2007137674A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2712168C1 (ru) * | 2015-12-18 | 2020-01-24 | БиЭмАй КОРЕЯ КО., ЛТД | Композиция для лечения остеоартрита, содержащая гидрофилизированный сульфасалазин и гиалуроновую кислоту, и способ получения такой композиции |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5088864B2 (ja) * | 2007-03-16 | 2012-12-05 | オリンパス株式会社 | 生体組織補填材とその製造方法 |
NO2252290T3 (ja) * | 2008-02-15 | 2018-04-28 | ||
US8343942B2 (en) | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
BRPI0909849A2 (pt) * | 2008-04-04 | 2015-10-06 | Univ Utah Res Found | éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los |
IT1393945B1 (it) | 2009-04-21 | 2012-05-17 | Fidia Farmaceutici | Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche |
US20120219554A2 (en) * | 2009-05-14 | 2012-08-30 | Fidia Farmaceutici S.P.A. | Extracellular yaluronidase from streptomyces koganeiensis |
IT1397247B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi agenti regolatori dell'attivita' citochinica |
IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
IT1397522B1 (it) * | 2009-12-21 | 2013-01-16 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento dell'osteoartrosi |
EP2384759A1 (en) * | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
US8546353B2 (en) | 2010-05-06 | 2013-10-01 | Glykos Finland Oy | Compounds and combinations |
AU2012230822A1 (en) | 2011-03-23 | 2013-11-07 | University Of Utah Research Foundation | Methods for treating or preventing urological inflammation |
US20140227235A1 (en) * | 2011-07-13 | 2014-08-14 | Cha Bio & Diostech Co., Ltd. | Cartilage cell treatment comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord |
TWI466675B (zh) | 2011-09-16 | 2015-01-01 | Univ China Medical | 用於抑制發炎之醫藥組合物 |
ITPD20120098A1 (it) * | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
CN104903344B (zh) * | 2012-09-20 | 2018-09-04 | 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 | Pedf衍生的多肽在治疗骨关节炎中的用途 |
US20140186306A1 (en) * | 2012-09-28 | 2014-07-03 | Paul Ronald Plante | Novel ampk agonist compositions and methods of use |
EP2981556A4 (en) * | 2013-04-02 | 2016-11-30 | Univ California | HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE |
WO2017171672A1 (en) | 2016-03-02 | 2017-10-05 | Bortek Bor Teknolojileri Ve Mekatronik Sanayi Ticaret Anonim Sirketi | Therapeutic mixtures for treating osteoarthritis comprising nano hexagonal boron nitride composition |
TWI632915B (zh) * | 2016-05-31 | 2018-08-21 | 大江生醫股份有限公司 | 用以治療關節炎之醫藥組成物 |
US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
WO2020055202A1 (ko) * | 2018-09-13 | 2020-03-19 | 주식회사 엘지화학 | 황산화 히알루론산 기반의 하이드로겔 및 이를 포함하는 약제학적 조성물 |
KR102542329B1 (ko) * | 2019-12-23 | 2023-06-13 | 주식회사 엘지화학 | 항염 또는 항혈관신생용 약제학적 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138572B1 (en) | 1983-10-11 | 1990-07-25 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
EP0754460B1 (en) | 1995-02-07 | 2002-06-05 | Shiseido Company Limited | Antiinflammatory agents |
EP0971961B1 (en) * | 1997-04-04 | 2002-12-04 | Fidia Advanced Biopolymers S.R.L. | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation |
IT1294797B1 (it) * | 1997-07-28 | 1999-04-15 | Fidia Advanced Biopolymers Srl | Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante |
US6645948B2 (en) | 1998-03-24 | 2003-11-11 | George D. Petito | Nutritional composition for the treatment of connective tissue |
US6476005B1 (en) | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
IT1302534B1 (it) * | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per |
IT1306644B1 (it) | 1999-04-08 | 2001-10-02 | Fidia Advanced Biopolymers Srl | Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico. |
US6288043B1 (en) * | 1999-06-18 | 2001-09-11 | Orquest, Inc. | Injectable hyaluronate-sulfated polysaccharide conjugates |
JP2001163789A (ja) * | 1999-12-13 | 2001-06-19 | Maruho Co Ltd | マトリックスメタロプロテアーゼ阻害用医薬組成物 |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
DE10053053A1 (de) | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
US6607745B2 (en) | 2001-05-18 | 2003-08-19 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
MXPA01011542A (es) | 2001-11-13 | 2003-05-22 | Alcon Inc | Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel. |
US20060094643A1 (en) * | 2002-07-03 | 2006-05-04 | Yuri Svirkin | Compositions of hyaluronic acid and methods of use |
CZ13928U1 (cs) | 2003-10-08 | 2004-01-20 | Cpn Spol. S R.O. | Dietetický přípravek pro prevenci a léčbu osteoporózy |
ITPD20040053A1 (it) * | 2004-02-27 | 2004-05-27 | Fidia Advanced Biopolymers Srl | Biomateriali costituiti da derivati dell'acido ialuronico come nuova terapia di cura per la protezione e la la riparazione della cartilagine articolare danneggiata per osteoartrosi |
-
2006
- 2006-05-31 IT IT000219A patent/ITPD20060219A1/it unknown
-
2007
- 2007-05-03 DK DK07724845T patent/DK2021078T3/en active
- 2007-05-03 CA CA2653660A patent/CA2653660C/en active Active
- 2007-05-03 SI SI200731640T patent/SI2021078T1/sl unknown
- 2007-05-03 ES ES14173163.8T patent/ES2619309T3/es active Active
- 2007-05-03 PL PL14173163T patent/PL2786782T3/pl unknown
- 2007-05-03 CN CN2007800196566A patent/CN101454048B/zh not_active Expired - Fee Related
- 2007-05-03 KR KR1020087029029A patent/KR20090014359A/ko active Search and Examination
- 2007-05-03 EP EP07724845.8A patent/EP2021078B1/en active Active
- 2007-05-03 ES ES07724845.8T patent/ES2534763T3/es active Active
- 2007-05-03 AU AU2007268195A patent/AU2007268195A1/en not_active Abandoned
- 2007-05-03 MX MX2008015212A patent/MX2008015212A/es active IP Right Grant
- 2007-05-03 SI SI200731910A patent/SI2786782T1/sl unknown
- 2007-05-03 US US12/302,511 patent/US20090197807A1/en not_active Abandoned
- 2007-05-03 WO PCT/EP2007/003920 patent/WO2007137674A1/en active Application Filing
- 2007-05-03 EP EP14173163.8A patent/EP2786782B1/en active Active
- 2007-05-03 PL PL07724845T patent/PL2021078T3/pl unknown
- 2007-05-03 JP JP2009512441A patent/JP5537933B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-06 HK HK09103222.5A patent/HK1123235A1/xx not_active IP Right Cessation
-
2012
- 2012-03-01 US US13/410,227 patent/US8765714B2/en active Active
-
2014
- 2014-04-11 US US14/251,318 patent/US9295690B2/en not_active Expired - Fee Related
- 2014-10-20 HK HK14110440A patent/HK1197040A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2712168C1 (ru) * | 2015-12-18 | 2020-01-24 | БиЭмАй КОРЕЯ КО., ЛТД | Композиция для лечения остеоартрита, содержащая гидрофилизированный сульфасалазин и гиалуроновую кислоту, и способ получения такой композиции |
Also Published As
Publication number | Publication date |
---|---|
WO2007137674A1 (en) | 2007-12-06 |
ES2534763T3 (es) | 2015-04-28 |
HK1197040A1 (en) | 2015-01-02 |
CA2653660A1 (en) | 2007-12-06 |
PL2786782T3 (pl) | 2017-08-31 |
ES2619309T3 (es) | 2017-06-26 |
EP2021078B1 (en) | 2015-02-25 |
US9295690B2 (en) | 2016-03-29 |
AU2007268195A1 (en) | 2007-12-06 |
SI2786782T1 (sl) | 2017-06-30 |
EP2786782A1 (en) | 2014-10-08 |
CA2653660C (en) | 2014-07-29 |
KR20090014359A (ko) | 2009-02-10 |
MX2008015212A (es) | 2008-12-09 |
EP2021078A1 (en) | 2009-02-11 |
US20090197807A1 (en) | 2009-08-06 |
ITPD20060219A1 (it) | 2007-12-01 |
PL2021078T3 (pl) | 2015-08-31 |
DK2021078T3 (en) | 2015-04-27 |
US20120165254A1 (en) | 2012-06-28 |
CN101454048B (zh) | 2013-06-19 |
CN101454048A (zh) | 2009-06-10 |
US8765714B2 (en) | 2014-07-01 |
JP2009538840A (ja) | 2009-11-12 |
EP2786782B1 (en) | 2017-03-08 |
HK1123235A1 (en) | 2009-06-12 |
US20140221294A1 (en) | 2014-08-07 |
SI2021078T1 (sl) | 2015-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5537933B2 (ja) | 変形性骨関節炎を治療するための硫酸化ヒアルロン酸 | |
US20040092479A1 (en) | Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage | |
EP1423081A2 (en) | Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints | |
Agiba | Nutraceutical formulations containing glucosamine and chondroitin sulphate in the treatment of osteoarthritis: Emphasis on clinical efficacy and formulation challenges | |
TWI516269B (zh) | 使用於炎症性腸疾病(ibd)治療和預防之透明質酸混合物 | |
JP2011037849A (ja) | 消化性潰瘍及び十二指腸潰瘍の治療及び予防に使用されるヒアルロン酸混合物 | |
Sayed Aly | Intra-articular drug delivery: a fast growing approach | |
WO2010121700A1 (en) | Compositions containing hyaluronic acid, sulphated hyaluronic acid, calcium and vitamin d3 for the treatment of osteoarticular and musculoskeletal disorders | |
WO2023001627A1 (en) | Dosage form for intra-articular injection comprising colchicine for use in the treatment of crystal-and non-crystal associated acute inflammatory arthritis | |
US9433575B1 (en) | Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis | |
WO2011160146A1 (en) | Pharmaceutical preparation containing dextran and sodium hyaluronate for the treatment of joint disorders | |
US20070142326A1 (en) | Treatment of a condition in a mammal with administration of aminosugar and uses thereof | |
JP2007507516A (ja) | アミノ糖投与による哺乳動物の障害の治療及びアミノ糖の使用 | |
CN114366807B (zh) | 一种用于预防和/或治疗骨关节炎的组合物 | |
JP5329866B2 (ja) | 医薬組成物及び関節障害の予防治療剤 | |
WO2024156699A1 (en) | Dosage form for intra-articular injection comprising colchicine for use in the treatment of a joint disease such as osteoarthritis | |
AU2002312564A1 (en) | Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130304 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130311 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131210 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140401 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5537933 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140428 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |